ARROWHEAD PHARMACEUTICALS, INC. Employee Benefits and Share-based Compensation
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Employee Benefits and Share-based Compensation of $807.94 million for the 125-month period ending 2013-09-30, per its 10-K filed 2013-12-18.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2013-12-18
- ARROWHEAD PHARMACEUTICALS, INC. employee benefits and share-based compensation for fiscal 2013 was $191.95M, a 18.12% increase from fiscal 2012.
- ARROWHEAD PHARMACEUTICALS, INC. employee benefits and share-based compensation for fiscal 2012 was $162.50M, a 277.90% increase from fiscal 2011.
- ARROWHEAD PHARMACEUTICALS, INC. employee benefits and share-based compensation for fiscal 2011 was $43.00M.
| Period end | Employee Benefits and Share-based Compensation 12 month | Employee Benefits and Share-based Compensation 12 month as first filed | Employee Benefits and Share-based Compensation 113 month | Employee Benefits and Share-based Compensation 125 month |
|---|---|---|---|---|
| 2013-09-30 | $191.95M 10-K · filed 2013-12-18 | $807.94M 10-K · filed 2013-12-18 | ||
| 2012-09-30 | $162.50M 10-K · filed 2013-12-18 | $162.00M 10-K · filed 2012-12-28 | $616.00M 10-K · filed 2012-12-28 | |
| 2011-09-30 | $43.00M 10-K · filed 2012-12-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |